Can I not stop taking Besudil mesylate tablets once I take them?

Belumosudil mesylate tablets (Belumosudil), as an immunomodulatory drug targeting ROCK2 kinase, is mainly suitable for patients aged 12 years and above with chronic graft-versus-host disease (cGVHD) who are refractory to glucocorticoids or other systemic treatments. After starting to use such targeted drugs, many patients worry about whether they must take them long-term or even lifelong. In fact, it is not that Besudil cannot be stopped once it is started, but the decision to stop it must be strictly based on individualized judgments based on the clinical condition, doctor's evaluation, and patient's treatment response.

According to the current overseas clinical medication guidelines and instructions, besudil should be taken orally once a day until the disease progresses or systemic therapy needs to be replaced. This means that the drug is not used indefinitely but is continuously evaluated based on disease activity and efficacy. If the patient's condition is stable during treatment, there is no new organ involvement, and the original symptoms are significantly improved, some doctors may try to gradually discontinue the drug based on the risk-benefit balance, especially in the context of other immunosuppressive drugs that have been reduced or even discontinued.

However, it should be emphasized that Besudil's regulation of the immune system is not a "one-time repair", but relies on continuous effects to maintain immune balance. Some patients may experience a resurgence of GVHD symptoms or worsening of organ function after stopping the drug without authorization or reducing the dose in advance. Therefore, any decision about stopping the drug must be made under the guidance of a professional doctor, and never stop using it on your own. In addition, changes in the condition should be closely monitored after discontinuation of medication, and rapid intervention is required if abnormalities are found.

To sum up, besudil is not a "lifelong dependence" drug, but it cannot be stopped lightly. It is a targeted treatment method based on dynamic management of the disease. Whether to discontinue treatment must comprehensively consider multiple dimensions such as disease stability, patient tolerance, and risk of complications to ensure a safe and standardized individualized treatment path.

Reference: https://www.drugs.com/pro/rezurock.html